ReviewAsia Pacific allergy2025
Nasal cytology in the rhinology-allergy clinic: From rhinitis to chronic rhinosinusitis with nasal polyps (CRSwNP).
Review in Asia Pacific allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Nasal cytology: Cornerstone and future directions in precision nasal disease management.Asia Pacific allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasal cytology (NC) has evolved into a standardized and clinically relevant diagnostic tool in rhinology, capable of characterizing the cellular patterns of allergic and nonallergic rhinitis, infectious rhinitis, and chronic rhinosinusitis with nasal polyps (CRSwNP). Through minimally invasive sampling and simple staining techniques, NC identifies distinct endotypes-such as nonallergic rhinitis with neutrophilic, nonallergic rhinitis with eosinophilis, nonallergic rhinitis with mast cell, and nonallergic rhinitis with eosinophils and mast cells-overcoming the limitations of conventional classifications and enabling targeted therapies. It also plays a decisive role in diagnosing overlapping rhinitis, a frequent cause of treatment failure. In CRSwNP, NC has contributed to defining the eosinophil-mast cell endotype and to developing the Clinical-Cytological Grading (CCG) and the Prognostic Index of Relapse (PIR), both correlating with disease severity and recurrence risk, while also aiding in the selection of candidates for biologic therapies. Its complementarity with histopathology has highlighted the importance of mast cells-often overlooked with standard hematoxylin-eosin staining-in the most severe disease phenotypes. Technological innovations, including artificial intelligence-assisted cell recognition, digital microscopy, phase-contrast analysis, and the nasal fern test, are enhancing diagnostic accuracy and reproducibility. Teaching remains essential, with hands-on training at the microscope under the guidance of expert tutors integrated into residency programs in otolaryngology, allergology, and pediatrics to ensure skill transfer and the incorporation of NC into clinical practice. Beyond morphology, NC bridges microscopic evidence with macroscopic clinical decisions, establishing itself as a cornerstone of precision medicine for upper airway diseases and as an indispensable tool in the rhinology and allergy clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.